长沙大宗USDT收购|【唯一TG:@heimifeng8】|飞机盗号软件VIP破解技术✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨EU approves Pfizer drug against respiratory syncytial virus
The European Commission of the European Union (EU) has approved Pfizer's ABRYSVO vaccine against respiratory syncytial virus (RSV. The vaccine is intended for the prevention of lower respiratory tract infections caused by RSV in adults aged 18-59 who are at high risk of the disease.
The expanded approval will apply to all 27 EU countries, Remedium reports.
In March, a group of experts from the European Medicines Agency made a positive decision on the approval of thus vaccine.
The registration of ABRYSVO has put rival GSK—which has yet to receive approval for its RSV vaccine for use in this patient group—in a difficult position.
Pfizer and GSK expect strong sales of their vaccines. Generic versions of the best-selling drugs will be available by the end of the decade.
In the US, however, sales of both vaccines fell sharply during the second autumn vaccination season.
Pfizer’s performance in the European market, however, has been more successful. The UK government has decided to supply about 5 million doses of ABRYSVO to England and Northern Ireland to vaccinate the elderly and pregnant women over the next two years.
Last week, the UK Health Security Agency publicized the first data from the start of this vaccination campaign in England in 2025. And the data presented show that the vaccine significantly reduces the number of hospitalizations among the elderly.